CD276 and neuroblastoma: Additionally, our findings were supported by the observation of higher B7-H3 expression in high-risk (GSE62564, n = 498, Supplementary Fig. S1B) and stage 4 NB patients (TARGET, n = 151, Fig. 1C; GSE45547, n = 649 [30], Supplementary Fig. S1C), as well as in patients with higher progression and deceased outcomes in the GSE16476 (n = 88) [28] and GSE62564 (n = 498) datasets (Supplementary Fig. S1D).